ClinicalTrials.gg
CompletedNCT00640627Updated Feb 2, 2021

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

A Phase 4 interventional study of Celecoxib and Placebo in Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 30 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
6th of 14
380 · median 216
Started
2003
with 2 others
Phase 4
10 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
6 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 6th largest by enrollment, is one of 3 that started in 2003, is one of 10 in phase 4, and was the 8th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OA of the knee in flare state at baseline visit and functional capacity class of I-III
  • Failed adequate trials of both naproxen and ibuprofen (prescription strength) within the past 5 years due to lack of efficacy, tolerability or both; duration of prescription strength ibuprofen and naproxen must have been a minimum of 2 weeks for each drug at the respective recommended doses if failure was due to lack of efficacy, and for any duration if failure was due to lack of tolerability

Exclusion criteria

Exclusion criteria:

  • Inflammatory arthritis or gout/pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Received acetaminophen within 24 hours of baseline visit
  • Use of mobility assisting device for less than six weeks prior to study screening or use of a walker
  • History of gastrointestinal (GI) perforation, obstruction, or bleeding
  • Diagnosed or treated for GI ulcer within 60 days prior to first dose of study medication
  • Recieved or hyaluronic acid within certain timeframe before study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • 200 mg oral capsule once daily for 6 weeks

  • DrugPlacebo

    Matched oral placebo for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in Patient's Assessment of Arthritis Pain, according to visual analog scale (VAS)

    Time frame: Week 6

Secondary outcomes

  1. Western Ontario and McMaster Universities Osteoarthritis Index

    Time frame: Week 6

  2. Patient's and Physician's Global Assessment of Pain

    Time frame: Weeks 2 and 6

  3. The Medical Outcomes Study Sleep Scale

    Time frame: Week 6

  4. Adverse events

    Time frame: Weeks 0-6

  5. Laboratory tests

    Time frame: Week 6

  6. Vital signs

    Time frame: Week 6

  7. Physical examination

    Time frame: Week 6

  8. Patient's Assessment of Arthritis Pain according to VAS

    Time frame: Week 2

  9. Serious adverse events

    Time frame: Up to 30 days after last dose

07

Study locations

30 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80904, United States
  • Pfizer Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Naples, Florida 34102, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33710, United States
  • Pfizer Investigational Site
    Woodstock, Georgia 30189, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66215, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70119, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21239, United States
  • Pfizer Investigational Site
    Flowood, Mississippi 39232, United States
  • Pfizer Investigational Site
    Chesterfield, Missouri 63017, United States
  • Pfizer Investigational Site
    Reno, Nevada 89502, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Pfizer Investigational Site
    Mason, Ohio 45040, United States
  • Pfizer Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Pfizer Investigational Site
    Camp Hill, Pennsylvania 17011, United States
  • Pfizer Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • Pfizer Investigational Site
    Greensboro, South Carolina 27401, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37601, United States
  • Pfizer Investigational Site
    Murfreesboro, Tennessee 37130, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
  • Pfizer Investigational Site
    Seattle, Washington 98133, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2008
First posted
Mar 21, 2008
Start
Dec 2003
CompletionActual
Sep 2004
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00640627
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Dec 2003
Completion
Sep 2004
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion